US Stock MarketDetailed Quotes

SGMT Sagimet Biosciences

Watchlist
  • 5.250
  • -0.690-11.62%
Close Dec 18 16:00 ET
  • 5.350
  • +0.100+1.91%
Pre 08:39 ET
169.03MMarket Cap-4.51P/E (TTM)

About Sagimet Biosciences Company

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Company Profile

SymbolSGMT
Company NameSagimet Biosciences
Listing DateJul 14, 2023
Issue Price16.00
Founded2006
CEOMr. David Happel
MarketNASDAQ
Employees10
Fiscal Year Ends12-31
Address155 Bovet Road,Suite 303
CitySan Mateo
ProvinceCalifornia
CountryUnited States of America
Zip Code94402
Phone1-650-561-8600
Websitehttp://www.sagimet.com

Company Executives

  • Name
  • Position
  • Salary
  • David Happel
  • President, Chief Executive Officer and Director
  • 2.69M
  • Elizabeth Rozek
  • General Counsel and Chief Compliance Officer
  • --
  • Thierry Chauche
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Eduardo Bruno Martins, D.Phil.,M.D.
  • Chief Medical Officer
  • 1.51M
  • George Kemble, PhD
  • Executive Chairman of the Board
  • 930.22K
  • Dr. Merdad V. Parsey, M.D.,PhD
  • Independent Director
  • 41.50K
  • Dr. Beth C. Seidenberg,M.D.
  • Independent Director
  • 14.38K
  • Jennifer Ann Jarrett
  • Independent Director
  • --
  • Dr. Anne M. Phillips, M.D.
  • Independent Director
  • --
  • Elizabeth Grammer
  • Independent Director
  • 43.00K
Heat List
US
Overall
Symbol
Price
% Chg

No Data